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Background: Prostate cancer is the most common cancer in older men in the United States (USA) and Western
Europe. Androgen deprivation (AD) constitutes, in most cases, the first-line of treatment for these cases. The
negative impact of CAD in quality of life, secondary to the adverse events of sustained hormone deprivation, plus
the costs of this therapy, motivated the intermittent treatment approach. The objective of this study is to to
perform a systematic review and meta-analysis of all randomized controlled trials that compared the efficacy and
adverse events profile of intermittent versus continuous androgen deprivation for locally advanced, recurrent or
metastatic hormone-sensitive prostate cancer.
Methods: Several databases were searched, including MEDLINE, EMBASE, LILACS, and CENTRAL. The endpoints
were overall survival (OS), cancer-specific survival (CSS), time to progression (TTP) and adverse events. We performed
a meta-analysis (MA) of the published data. The results were expressed as Hazard Ratio (HR) or Risk Ratio (RR), with
their corresponding 95% Confidence Intervals (CI 95%).
Results: The final analysis included 13 trials comprising 6,419 patients with hormone-sensitive prostate cancer. TTP
was similar in patients who received intermittent androgen deprivation (IAD) or continuous androgen deprivation
(CAD) (fixed effect: HR = 1.04; CI 95% = 0.96 to 1.14; p = 0.3). OS and CSS were also similar in patients treated with
IAD or CAD (OS: fixed effect: HR = 1.02; CI 95% = 0.95 to 1.09; p = 0.56 and CSS: fixed effect: HR = 1.06; CI 95% = 0.96
to 1.18; p = 0.26).
Conclusion: Overall survival was similar between IAD and CAD in patients with locally advanced, recurrent or
metastatic hormone-sensitive prostate cancer. Data on CSS are weak and the benefits of IAD on this outcome
remain uncertain. Impact in QoL was similar for both groups, however, sexual activity scores were higher and the
incidence of hot flushes was lower in patients treated with IAD.
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Prostate cancer is the most common cancer in older
men in the United Kingdom (UK), United States
(USA) and Western Europe [1]. Despite its high inci-
dence, the disease is often responsive to treatment
even when metastatic and may be cured when local-
ized. In patients with locally advanced tumors, recur-
rent or metastatic, the goals of therapy are to prolong
survival, slow the progression of disease and preserve
the quality of life [2].
Androgen deprivation (AD) constitutes, in most cases,
the first-line of treatment for these cases. However, the
deleterious effects of continuous androgen deprivation
(CAD) are widely known and are related to some degree
of deterioration in the quality of life. The most frequent
symptoms resulting from AD include sexual dysfunction,
fatigue, anemia, reduced muscle and bone mass, depres-
sion, abnormal lipid metabolism, cognitive dysfunction
and development or worsening of metabolic syndrome
[3,4]. The negative impact of CAD in quality of life, sec-
ondary to the adverse events of sustained hormone
deprivation, plus the costs of this therapy, motivated the
intermittent treatment approach.
In recent years, non-randomized studies (most of them
with heterogeneous criteria for selection and clinical as-
sessment) were performed to confirm the effectiveness
of intermittent androgen deprivation (IAD) in patients
with prostate cancer. Two systematic reviews [5,6] previ-
ously published analyzed the results of these non-
randomized studies and the authors suggested that the
best candidates for intermittent androgen deprivation
are patients with biochemical progression after prosta-
tectomy or radiation, with no evidence of metastases
and with mildly aggressive tumors. On the other hand,
patients with large tumor volumes, positive lymph nodes
and bone metastases, PSA >100 ng/ml or short PSA
doubling time, would be best treated with continuous
deprivation.
Irrespective of official guideline recommendations,
IAD is a treatment option used worldwide by both urol-
ogists and oncologists even outside of clinical trials [5].
The 2008 UK National Institute for Health and Clin-
ical Excellence (NICE) recommends that IAD may be of-
fered to men with metastatic prostate cancer providing
they are informed that there is no long-term evidence of
its effectiveness [7].
The results of some randomized controlled trials (RCT)
were statistically inconclusive [8] or controversial. Crook
et al. [9,10] analyzed IAD versus CAD for prostate-specific
antigen (PSA) elevation after radiotherapy, assessing overall
survival (OS) in a non-inferiority randomized trial with
1,386. The results demonstrated that IAD was non-inferior
to CAD in regard to OS (8.8 years versus 9.1 years respect-
ively - hazard ratio for death, 1.02; CI 95% 0.86 to 1.21, p fornon-inferiority = 0.009), besides providing potential bene-
fits in aspects such as physical function, fatigue, urinary
problems, hot flashes, libido, and erectile function. Fur-
thermore, the authors pointed that time to hormone re-
sistance was statistically significantly improved on the
IAD arm (HR 0.80, 95% CI 0.67-0.98; p = 0.024).
Regarding time-to-progression or castration-resistant
disease, however, Crook et al. [9,10] showed better re-
sults in favor of CAD, while the results of Salonen et al.
[11,12] were favorable to IAD. Such contradictory results
make it difficult to emit a strong scientific-based recom-
mendation for or against IAD.
The objective of this study is to analyze all published
randomized controlled trials (RCTs) that compared the
efficacy and adverse events profile of IAD versus CAD





We included RCTs with parallel design that compared
the use of intermittent versus continuous androgen
deprivation.
Types of participants
The selected studies included patients with locally ad-
vanced, recurrent or metastatic hormone-sensitive pros-
tate cancer.
Search strategy for identification of studies
A wide search on the main computerized databases was
conducted, including EMBASE, LILACS, MEDLINE,
SCI, CENTRAL, The National Cancer Institute Clinical
Trials service and The Clinical Trials Register of Trials
Central. In addition, the abstracts published in the pro-
ceedings of the American Society of Clinical Oncology
(ASCO), American Society of Radiation Oncology
(ASTRO), the European Society of Medical Oncology
(ESMO), Society of Urologic Oncology (SUO), European
Society for Radiotherapy and Oncology (ESTRO) and
American Urological Association (AUA) were also
searched.
For MEDLINE, we used the search strategy method-
ology for randomized controlled trials [13] recom-
mended by the Cochrane Collaboration [14]. For
EMBASE, adaptations of this same strategy were used
[13], and for LILACS, we used the search strategy meth-
odology reported by Castro et al. [15]. An additional
search on the SCI database was also performed to re-
trieve articles that were cited on the included studies.
The specific terms relevant to this review were added to
the overall search strategy methodology for each
database.
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#2: intermittent, #3: androgen deprivation and #4: Ran-
domized Controlled Trial. Searches in electronic data-
bases combined the terms: #1 AND #2 AND #3 AND
#4.
The search was not limited by date, language or spe-
cific outcome.
Critical evaluation of the selected studies
All the references retrieved by the search strategies had
their title and abstract evaluated by two of the re-
searchers. Every reference with the least indication of
fulfilling the inclusion criteria was listed as pre-selected.
The complete article of all pre-selected references was
retrieved. The articles were analyzed by two different re-
searchers and included or excluded according to the pre-
viously reported criteria. The excluded trials and the
reason of their exclusion are listed in this article. Data
was extracted from all the included trials.
Details regarding the main methodology characteristics
empirically linked to bias [16] were extracted with the
methodological validity of each selected trial assessed by
two reviewers (T.E.A.B and O.C). Particular attention
was given to some items such as: the generation and
concealment of the sequence of randomization; blinding;
application of intention-to-treat analysis; sample size
pre-definition; loss of follow-up description; adverse
events reports; if the trial was performed in multiple
center or a single center; and the sponsorship.
Data extraction
Two independent reviewers extracted the data. The
name of the first author and year of publication were
used to identify the study. All data were extracted dir-
ectly from the text or calculated from the available infor-
mation when necessary. The data of all trials were based
on the intention-to-treat principle, so they compared all
patients allocated in one treatment with all those allo-
cated in the other.
The primary endpoint was overall survival (OS). The
OS was calculated from the date of randomization to the
date of death, with data censored at the last known date
that the patient was alive.
Other clinical outcomes were also evaluated:
 Cancer-specific survival (CSS): the cancer-specific
survival was calculated from the date of
randomization to the date of death from prostate
cancer or a complication of cancer treatment;
 Time to progression (TTP) or castration-resistant
disease: defined as increases in PSA level or evidence
of new clinical disease while the patient was receiving
androgen-deprivation therapy and testosterone was at
castration level; Differences in the quality of life (QoL): hot flashes,
desire for sexual activity, urinary symptoms,
depression and gynecomastia;
 Died because of cardiovascular events.
Analysis and presentation of results
Data analysis was performed using the Review Manager
5.1.2 statistical package (Cochrane Collaboration Soft-
ware) [17].
Dichotomous clinical outcomes are reported as Risk
Ratio (RR) and survival data as Hazard Ratio (HR) [18].
The corresponding 95% confidence interval (CI 95%)
was calculated, considering P values less than 5% (p <
0.05). Statistic Heterogeneity was calculated through I2
method (25% was considered low-level heterogeneity,
25-50% moderate-level heterogeneity and >50% high-
level heterogeneity) [19,20].
To estimate the absolute gain in OS, cancer-specific
survival and time to progression, the meta-analytic
survival curves were calculated as suggested by Parmar
et al. [18]. A pooled estimate of the HR was computed
by a fixed-effect model according to the inverse-variance
method [21]. Thus, for effectiveness or adverse events,
an HR or RR >1 favors the standard arm (continuous
treatment) whereas an HR or RR <1 favors the intermit-
tent treatment.
If statistic heterogeneity was found in the meta-
analysis, an additional analysis was performed, using the
random-effects model described by DerSimonian and
Laird [22] that provides a more conservative analysis.
To assess the possibility of publication bias, the funnel
plot test described by Egger et al. was performed [23].
When the pooled results were significant, the number of
patients needed to treat (NNT or NNH) to cause or to
prevent one event was calculated by pooling absolute
risk differences in the trials included in this meta-
analysis [24-26]. For all analyses, a forest plot was gener-
ated to display the results.
Results
The diagram represents the flow of identification and in-
clusion of trials, as recommended by the PRISMA (Pre-
ferred Reporting Items for Systematic reviews and Meta-
Analyses) statement [27] (Figure 1).
Overall, 73 references were identified and screened.
Twenty-nine studies were selected and retrieved for
full-text analysis. Of these studies, 16 were excluded for
various reasons described on Table 1.
Characteristics of included studies
Thirteen randomized trials comprising 6,419 patients with
hormone-sensitive prostate cancer were included in this
analysis. More than 2,800 patients (44%) had metastatic dis-
ease and 1,595 patients (25%) had PSA progression after
Figure 1 Trial selection flow.
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number of patients in these trials varied from 43 to 1,535,
but only 5 involved >500 patients. The average age of pa-
tients was 70 years.
PSA was measured every 2-3 months in most studies
[1,9-12,44-54]. Only in one study [8,55] PSA levels were
measured monthly.
Full details of trial design are not available for all stud-
ies: several reports are available only in abstract form
[48,49,56].
The criteria for stopping and re-start of therapy in
groups treated with IAD were similar, however not uni-
form (Table 2). Average follow-up time in these studies
was of >2 years. The induction period varied, but mostTable 1 Characteristics of excluded studies
Study Reason for exclusion
Klotz [28] Not a randomized trial
Goldenberg [29] Not a randomized trial
Higano [30] Not a randomized trial
Oliver [31] Not a randomized trial
Bierkens [32] Not a randomized trial
Grossfeld [33] Not a randomized trial
Calais da Silva Jr F [34] Analysis of pooled data from 2 trials
De Conti P [35] Systematic Review
Loblaw [36] Practice guideline
Heidenreich [37] Practice guideline
Heidenreich [38] Not a randomized trial
Heidenreich [39] Practice guideline
Buchan [40] Not a randomized trial
Keizman [41] Not a randomized trial
Gruca [42] Literature review
Organ [43] Castration-resistant prostate cancerpatients used IAD for a period of approximately 3-
6 months (Table 3).
Two studies [48,49,54] did not use luteinizing hor-
mone–releasing hormone agonist (LHRHa) or orchiec-
tomy. These studies used cyproterone acetate (CPA)
with doses between 300-400 mg/day orally. Overall,
goserelin was the most used LHRHa, followed by leu-
prorelin (Table 3).
Evaluation of OS was the primary endpoint in 4 studies
[8-10,50,55,58] and TTP or time to androgen-independent
was the primary endpoint in 7 studies [1,11,12,44-47,50-54,
56,57] (Table 2). Five studies [1,8-10,44-47,55,58] were de-
signed to evaluate the non-inferiority of IAD compared to
CAD (Table 4).
More details on the treatment modality, follow-up,
number of patients and primary endpoint in the 13 trials
included in this analysis are summarized in Tables 2
and 3.
The efficacy analysis was summarized in Table 4.
Meta-analysis
Overall, TTP was similar in patients who received IAD or
CAD (fixed effect: HR = 1.04; CI 95% = 0.96 to 1.14;
p = 0.3), with high moderate heterogeneity (Chi2 = 13.59,
df = 8 [P = 0.09]; I2 = 41%) (Figure 2).
OS and CSS were also similar in patients treated with
IAD or CAD (OS: fixed effect: HR = 1.02; CI 95% = 0.95
to 1.09; p = 0.56 with moderate heterogeneity Chi2 =
9.57, df = 7, P = 0.21, I2 = 27% and CSS: fixed effect:
HR = 1.06; CI 95% = 0.96 to 1.18; p = 0.26 also with mod-
erate heterogeneity Chi2 = 9.75, df = 6, P = 0.14, I2 = 38%
(Figures 3 and 4, respectively).
In order to explore this heterogeneity, the study by
Salonen et al. [11,12] was removed from the survival
analysis, since patients treated in the IAD arm had lower
levels of baseline PSA than patients on CAD group
(IAD: mean PSA 116.0 ± 173.4 ng/ml; CAD: mean PSA
Table 2 Characteristics of randomized included studies
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similar between the groups (fixed effect: HR = 1.04; CI
95% = 0.96 to 1.12; p = 0.32) while there was a decrease
in heterogeneity (Chi2 = 6.87, df = 5, P = 0.23, I2 = 27%).
Furthermore, CSS was favorable to CAD (fixed effect:
HR = 1.16; CI 95% = 1.02 to 1.31; p = 0.02; NNT = 6) with
no heterogeneity (Chi2 = 3.51, df = 5, P = 0.62, I2 = 0%).
Four studies [8,48-50,54,55] included only patients
with metastatic disease (or ≥90% metastatic). In this sub-
group of patients, only 1 study [50] reported TTP data
and another [54] reported cancer-specific survival data,
so a meta-analysis was not feasible. Two studies
[8,50,55] reported OS data, which permitted meta-
analysis. OS was also similar in patients treated with
IAD or CAD (fixed effect: HR = 1.10; CI 95% = 0.98 to
1.24; p = 0.11) with no heterogeneity (Chi2 = 0.02, df = 1,
P = 0.88, I2 = 0%).Two studies [1,9,10,46,47] included only patients with
recurrent disease after definitive local therapy (prostatec-
tomy or radiotherapy). In this subgroup, TTP was favor-
able to patients who received CAD (fixed effect: HR =
1.19; CI 95% = 1.01 to 1.39; p = 0.03), with moderate het-
erogeneity (Chi2 = 1.57, df = 1 [P = 0.21]; I2 = 36%). How-
ever, when the random-effects model analysis was
performed, no significant difference was detected (ran-
dom effects: HR = 1.16, CI95% = 0.92 to 1.45; p = 0.22).
It was not possible to perform a meta-analysis for OS
and CSS, since only Crook et al. [9,10] reported these
data.
One study [58], on re-introduction of treatment in
IAD group, used a hormone therapy scheme (cyproter-
one 300 mg/d) that was different from the one used in
the CAD group (LHRHa: triptoreline 11.25 mg plus cy-
proterone 200 mg/d). When OS analysis was performed
Table 3 Treatment regimens in the included studies
Crook 2012 (CIC-CTG PR.7 Trial) [9,10] Intermittent: induction only (8 mo): LHRHa injections plus a non-steroidal antiandrogen, with the latter
continued for a minimum of 4 weeks.
Continuous: consisted of a LHRHa plus a non-steroidal antiandrogen, with the latter continued for a
minimum of 4 weeks, or orchiectomy.
Calais da Silva 2009/2011
(SEUG 9401 Trial) [44,45]
Intermittent: induction only (3 mo): CPA 200 mg for 2 weeks followed by monthly depot injections of a
LHRHa plus 200 mg of CPA daily.
Continuous: received an LHRHa plus 200 mg of CPA daily.
Hussain 2013 (SWOG 9346 Trial) [8,55] Intermittent: induction only (7 mo): received LHRHa (goserelin) plus bicalutamide.
Continuous: LHRHa plus bicalutamide
Salonen 2012/2013 (FinnProstate
Study VII) [11,12]
Intermittent: induction only (6 mo): goserelin acetate (3.6 mg) SC every 28 days. The CPA was given in
100 mg twice daily during the first 12.5 days to minimize flare reaction.
Continuous: continued with goserelin acetate or bilateral orchiectomy.
Tunn 2012 (EC507 Trial) [1,46,47] Intermittent: induction only (6 mo): received LHRHa (Leuprorelin acetate 11.25 mg, 3-mo depot, SC or IM)
plus CPA 200 mg/day orally was administered for the first 4 weeks to prevent tumor flare.
Continuous: LHRHa
De Leval 2002 [51] Intermittent: induction only (3-6 mo): flutamide (250 mg, 3 times, daily) for 15 days. This therapy was
followed by flutamide and goserelin acetate (3.6 mg, monthly).
Continuous: goserelin plus flutamide (250 mg orally every 8 hours) without interruption.
Langenhuijsen 2008/2011
(TULP Trial) [52,53]
Intermittent: induction only (6 mo): Buserelin depot 6.6 mg, a 2-monthly SC plus nilutamide 300 mg
(once a day for the first 4 weeks and 150 mg daily thereafter).
Continuous: buserelin depot plus nilutamide
Miller 2007 [56] Intermittent: induction only (6 mo): goserelin plus bicalutamide
Continuous: goserelin plus bicalutamide
Mottet 2012 (TAP 22 Trial) [50] Intermittent: induction only (6 mo): leuprorelin SR 3.75 mg, SC every 28 days and flutamide, one 250 mg
tablet, three times daily.
Continuous: leuprorelin and flutamide continued until disease progression or study end.
Verhagen 2008/2013 [48,49] Intermittent: induction only (3-6 mo): CPA 100 mg three times daily
Continuous: CPA 100 mg thrice daily.
Hering 2000 [54] Intermittent: induction only (10.5 mo): CPA 200 mg/day orally
Continuous: CPA 200 mg/day orally
Irani 2008 [57] Intermittent: induction only (6 mo): goserelin 10.8 mg 3-mo depot and flutamide 250 mg three times daily
and resumed 6 mo later
Continuous: goserelin and flutamide 250 mg three times daily continued without interruption
Silva 2013 (SEUG 9901 Trial) [58] Intermittent: induction only (3 mo): CPA 200 mg/d for 2 weeks followed by monthly depot injections of
triptoreline plus 200 mg of CPA daily and restarted monotherapy with CPA 300 mg/d in the progression
Continuous: CPA 200 mg/d for 2 weeks followed by monthly depot injections of triptoreline plus 200 mg of
CPA daily.
Abbreviations: Mo months, CPA cyproterone acetate, LHRHa luteinizing hormone–releasing hormone agonist, SC subcutaneous, IM intramuscular injection.
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IAD and CAD (fixed effect: HR = 1.04; CI 95% = 0.97 to
1.12; p = 0.25; with no heterogeneity: Chi2 = 7.08, df = 6,
P = 0.31, I2 = 15%).
In most studies [8-10,44,48-50,55] baseline quality-of-
life scores were similar in both groups for the majority
of items, with no clinically significant differences. Sexual
activity scores appeared to be favorable in the IAD group
(Table 5).
The prevalence of adverse events of androgen deprivation
such as hot flushes (fixed effect: RR = 0.86; CI 95% = 0.82 to
0.90; p < 0.00001), gynecomastia (fixed effect: RR = 0.72; CI95% = 0.65 to 0.80; p < 0.00001) and headache (fixed effect:
RR = 0.81; CI 95% = 0.68 to 0.97; p-0.02) were more fre-
quent in patients treated with CAD, with high heterogen-
eity levels (Figure 5). As planned, a random-effects model
analysis was performed to better explore this heterogeneity.
In this analysis, with exception of hot flushes (RR = 0.65;
CI 95% = 0.45 to 0.95; p = 0.03; NNH= 10), adverse events
were similar in both groups (gynecomastia: RR = 0.66; CI
95% = 0.39 to 1.13; p = 0.13 and headache: RR = 0.68; CI
95% = 0.42 to 1.10; p = 0.11).
Mortality secondary to cardiovascular events was report
in only 4 studies [9-12,44,45,58]. Results of this analysis
Table 4 Efficacy analysis in the trials included in the meta-analysis
Study Arm Design of study Time to progression or time to
castration-resistant disease
Cancer-specific survival Overall survival (95% CI)
Crook 2012 [9,10] (CIC-CTG PR.7 Trial) CAD Non-inferiority 10 years HR: 1.18 (0.90-1.55) 9.1 years





(IAD vs CAD ≥1.25) = 0.009
Calais da Silva 2009/2011 [44,45] (SEUG Trial) CAD Non-inferiority HR: 0.81 (0.63-1.05)
favoring CAD
HR: 1.27 (0.98-1.64) HR: 0.96 (0.80-1.14)
favoring CAD
IAD (<30%)
Hussain 2013 [8,55] (SWOG 9346 Trial) CAD Non-inferiority NR NR 5.8 years
IAD (HR <1.20) 5.1 years
HR: 1.10 (0.97-1.25)
Salonen 2012/2013 [11,12] CAD Compare the efficacy 30.2 months 44.3 months 45.7 months





HR: 1.15 (0.94 -1.4)
favoring IAD
Tunn 2012 [1,46,47] (EC507 Trial) CAD Non-inferiority 16 risk of progression NR NR
IAD 37 risk of progression
p = 0.853
HR: 0.97 (0.68-1.38) &
De Leval 2002 [51] CAD Compare the efficacy 14.4 months 4 (12.1%) deaths NR
IAD 25.7 months 2 (5.7%) deaths
HR: 0.57 (0.07-4.64) & NS
HR: 0.46 (0.09-2.35) &
Langenhuijsen 2008/2011 [52,53] CAD Compare the efficacy 24.1 months# NR NS
(TULP Trial) IAD 18 months
NS
Miller 2007 [56] CAD Compare the efficacy 11.5 months NR 53.8 months
IAD 16.6 months 51.4 months
p = 0.1758 p = 0.658

















Table 4 Efficacy analysis in the trials included in the meta-analysis (Continued)
Mottet 2012 [50] (TAP 22 Trial) CAD Compare the efficacy 15.1 months NR 52 months
IAD 20.7 months 42.2 months
p = 0.74 p = 0.75
HR: 0.88 (0.63-1.4)& HR: 1.14 (0.74-1.77)&
Verhagen 2008/2013 [48,49] CAD Compare the efficacy NS NS NS
IAD
Hering 2000 [54] CAD Compare the efficacy 20.1 months 2 (11.1%) deaths NR
IAD NR 2 (8%) deaths
NS NS
HR: 0.70 (0.09-5.44) &












CAD Non-inferiority HR: 1.16 (0.93-1.47) HR: 1.0 (0.76-1.32) HR: 0.90 (0.76-1.07)
IAD (HR < 1.20)
Abbreviations: ITT intention-to-treat, HR Hazard ratios, Mo months, NS not significant, IAD intermittent androgen deprivation, CAD continuous androgen deprivation.
#No hazard ratio or P value reported.

















Figure 2 Time-to-progression: comparative effect of intermittent versus continuous androgen deprivation in prostate cancer.
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RR = 0.80; CI 95% = 0.67 to 0.94; p = 0.007; NNH= 33)
however with high heterogeneity levels (Chi2 = 6.67, df = 3
[P = 0.08]; I2 = 55%).
According to funnel plot analysis [23] the possibility of
publication bias was low for all of the outcomes. When fun-
nel plot shows asymmetry, there is a possibility of bias and
despite its limmitations, this method is widely used by
authors.
Discussion
Currently, many oncology guidelines do not recommend
the use of IAD for patients with metastatic hormone-
sensitive prostate cancer [36,59]. But it is important to note
that these guidelines date back to 2007. Guidelines from
the European Association of Urology (EUA) state that IAD
is now widely offered to patients with prostate cancer and
should no longer be regarded as investigational [60,61].
Two other meta-analysis published earlier [62,63] showed
that both treatments had similar results regarding OS and
CSS. Analysis of OS was performed with 4 studies
[8-12,44,45,55] in the Niraula et al. meta-analysis [62] and 7
studies [8-12,44,45,50,52,53,55,57] in Tsai et al. [63]. CSSFigure 3 Overall survival. Comparative effect of intermittent versus contianalysis was performed with 3 [9-12,44,45] and 6 studies
[8-12,44,45,51,55,57] respectively.
In this present meta-analysis, we included a larger num-
ber of studies. When HRs were not directly reported in
the original study, they were estimated indirectly by using
the reported number of events and the corresponding P
value for the log-rank statistics, or by reading survival
curves as suggested by Parmar et al. [18]. To reduce
reading errors, original survival curves were digitalized
and enlarged, and data extraction was based on reading
electronic coordinates for each point of interest, as de-
scribed by DeLaurentiis in another meta-analysis [64].
In the final OS and CSS analyses we included 8 and 7
studies respectively. The induction time of androgen
deprivation was, in general, 3-6 months. Two studies were
available only in abstract form [48,49,56]. Overall, goserelin
was the most used LHRHa, followed by leuprorelin. Only
two studies [48,49,53] did not used luteinizing hormone–
releasing hormone agonist (LHRHa) or orchiectomy. These
studies used cyproterone acetate (CPA).
In this meta-analysis, randomized studies included het-
erogeneous groups of patients (locally advanced, metastatic
or recurrent). It was not possible to perform the propernuous androgen deprivation in prostate cancer.
Figure 4 Cancer-specific survival. Comparative effect of intermittent versus continuous androgen deprivation in prostate cancer.
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http://www.biomedcentral.com/1471-2490/14/9analysis of subgroups of patients (i.e. by Gleason score, ini-
tial PSA levels, minimal or extensive metastatic disease) be-
cause results for such sets were not published in the
studies. As to overall survival, our results reinforce the
equivalent efficacy of CAD and IAD, regardless of previous
treatments.Table 5 Significant differences in quality of life (QoL)
Study EORTC quality-of-life co
Crook 2012 [9,10] (CIC-CTG PR.7 Trial) Intermittent (better): hot
Continuous: -
Calais da Silva 2009/2011 [44,45] (SEUG Trial) Intermittent (better): sex
Continuous (better): emo
Hussain 2013 [8,55] (SWOG 9346 Trial) Intermittent (better): ere
Continuous: -
Salonen 2012/2013 [11,12] (FinnProstate Trial VII) Intermittent (better): sex
Continuous: -
Tunn 2012 [1,46,47] (EC507 Trial) Intermittent: NR
Continuous: NR
De Leval 2002 [51] Intermittent: NR
Continuous: NR
Langenhuijsen 2008/2013 [52,53] (TULP Trial) Intermittent: NS
Continuous: NS
Miller 2007 [56] Intermittent (better): sex
Continuous: -
Mottet 2012 [50] (TAP 22 Trial) Intermittent: NS
Continuous: NS
Verhagen 2008/2013 [48,49] Intermittent (better): sym
Continuous: -
Hering 2000 [54] Intermittent (better): ere
Continuous: -
Irani 2008 [57] Intermittent (better): abi
Continuous: -
Silva 2013 [58] (SEUG 9901 Trial) Intermittent (better): sex
Continuous: -
Abbreviations: EORTC European Organization for Research and Treatment of Cancer,Apropos of CSS, despite the overall analysis demonstrat-
ing only a trend towards treatment with CAD, the results
must be interpreted with caution. As mentioned before, in
one of the studies [11,12] the baseline PSA levels were
lower on the IAD arm, suggesting that these patients had
less extensive disease. Once this trial was excluded fromre questionnaire (QLQ-C30) and the EORTC Prostate Cancer Module
flashes, desire for sexual activity, and urinary symptoms
ual function
tional domain, nausea and vomiting, severity of insomnia
ctile function and mental health at 3 months but not thereafter
ual function
ual activity appeared to be favorable in the intermittent
ptom and potency scales
ctile function
lity to have and maintain an erection.
ual activity
NS not significant, NR not reported.
Figure 5 Toxicities. Comparative effect of intermittent versus continuous androgen deprivation in prostate cancer.
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http://www.biomedcentral.com/1471-2490/14/9the analysis, results favored the group treated with CAD;
therefore we cannot exclude the possibility that IAD may
carry a higher risk of death by cancer.
Recently, a large prospective Danish study, including over
30,000 patients, investigated the relationship between an-
drogen deprivation therapy (ADT) and cardiovascular dis-
eases such as myocardial infarction (MI) and stroke in men
with prostate cancer [65]. The authors found that patients
treated with medical endocrine therapy had an increased
risk for MI and stroke with adjusted HRs of 1.31 (95% con-
fidence interval [CI], 1.16-1.49) and 1.19 (95% CI, 1.06-
1.35), respectively, compared with nonusers of ADT. How-
ever, androgen deprivation secondary to orchiectomy didno increase the risks for MI (HR: 0.90; 95% CI, 0.83-1.29)
or stroke (HR: 1.11; 95% CI, 0.90-1.36). Nevertheless, the
conclusions might have been affected, by the lack of infor-
mation on prognostic lifestyles.
In this meta-analysis, mortality secondary to cardio-
vascular diseases, despite the heterogeneity found and
the paucity of studies reporting this outcome, was
favorable to the group treated with IAD. This aspect
might have influenced the similar results achieved in
OS.
In the event of biochemical recurrence after pros-
tatectomy, when androgen deprivation is indicated, the
best candidates for IAD are patients who reach PSA
Botrel et al. BMC Urology 2014, 14:9 Page 12 of 14
http://www.biomedcentral.com/1471-2490/14/9values <0.5 ng/mL after the induction time, according
to a randomized study that was considered pure
(i.e which included only patients with recurrence after
prostatectomy) [1,46,47]. For biochemical recurrences
after radiotherapy, the best candidates for IAD are pa-
tients who reach PSA levels <4 ng/mL after the induction
time [9,10]. Only in these situations (recurrence after
radiotherapy or prostatectomy), TTP seems to be favor-
able to patients receiving CAD. In locally advanced and/or
metastatic tumors, the best candidates for IAD are
patients who reach PSA values <4 ng/mL after induction
time.
Although TTP analysis was performed in this meta-
analysis, the results should be evaluated with caution
since criteria for progression were different among the
included studies.
Patients with a lower burden of disease (i.e. less exten-
sive diseases) and without co-morbidities may be the
ones achieving most benefits with IAD treatment.
The implementation of guidelines to assess, monitor
and reduce known risk factors for cardiovascular disease
may influence the results of overall survival in patients
treated with CAD.
Regarding quality of life, differences were not clinically
significant in most studies. But it was observed that sex-
ual activity scores seemed to be higher in patients
treated with IAD, and the incidence of hot flushes was
lower.
Furthermore, it is important to note that IAD modality
offers an economic benefit with reduction of pharma-
ceutical costs during “off-therapy” [62]. Economic ana-
lysis is not the aim of this investigation. The studies
included failed to report the costs of both modalities
(intermittent and continuous). Niraula et al. [62], analyz-
ing only drug costs, estimated that the median cost sav-
ings with IAD would be 48%. Hering et al. [54], also
based only on the average drug costs, demonstrated that
the cost of treatment in IAD arm was approximately
50% lower that in the CAD, over 48 months.
Conclusions
Overall survival was similar between IAD and CAD in pa-
tients with locally advanced, recurrent or metastatic
hormone-sensitive prostate cancer. Data on CSS are weak
and the benefits of IAD on this outcome remain uncer-
tain. Impact in QoL was similar for both groups, however,
sexual activity scores were higher and the incidence of hot
flushes was lower in patients treated with IAD.
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